Status: Planned
First registered on:
16/09/2019
Last updated on:
31/03/2020
1. Study identification
EU PAS Register NumberEUPAS31405
Official titleA pragmatic, cluster randomized trial evaluating the impact of an enhanced adherence package (dual bronchodilator+add-on+app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year
Study title acronymMAGNIFY
Study typeClinical trial
Brief description of the studyNot taking medications as prescribed is an issue affecting patients irrespective of disease and treatment type and can lead to poor clinical outcomes such as worsening symptoms. In COPD, guidelines have noted the importance of supporting patients with their regular inhaler use as part of COPD management.
This study (MAGNIFY) will enable randomly selected GP practices to support COPD inhaler use in their patients through a new technology by Propeller Health (US). This technology includes a device which is attached to the Ultibro® inhaler, monitors inhalations and sends reminders to the user’s smartphone to take their daily dose. As part of this research, the device can be offered to suitable patients for 12 months. At the
end of the study, researchers will assess the impact of the technology on clinical outcomes such as COPD exacerbations and medication use. Outside this research, the technology is currently available to healthcare providers in the UK through programs with Propeller Health with a range of inhalers.
The study aims to recruit 176 GP practices in the UK and collect non-identifiable data from 2624 people. Half
of the participating GP practices will be randomly selected to receive access to the technology. The other GP practices will continue their usual patient care.
The study does not involve any visits outside usual care. Data will be extracted from the participating GP practices’ routine medical records at each site at the beginning of the study and regularly until the end of the study. All data will be stored in an ethically approved Optimum Patient Care Research Database (https://opcrd.co.uk). Any data shared with the researchers will be fully de-identified.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableISRCTN Study ID: ISRCTN10567920
ADEPT Approval: ADEPT0719
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupObservational and Pragmatic Research Institute Pte Ltd
Organisation/affiliationOPRI Pte Ltd
Details of (Primary) lead investigator
Title Professor
Last name Jones
First name Rupert
Is this study being carried out with the collaboration of a research network?
Yes
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?176
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed13/06/2019
Start date of data collection01/03/2020
Start date of data analysis
Date of interim report, if expected
Date of final study report15/12/2021
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesNovartis Pharma AG80
Charities
Government body
Research councils
EU funding scheme
OtherOPRI Pte Ltd20
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Jones
First name Rupert
Address line 1University of Plymouth
Address line 2N14, ITTC Building
Address line 3Davy Road,
CityPlymouth, Devon
PostcodePL6 8BX
CountryUnited Kingdom
Phone number (incl. country code)01752764403
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Jones
First name Rupert
Address line 1University of Plymouth
Address line 2N14, ITTC Building
Address line 3Davy Road,
CityPlymouth, Devon
PostcodePL6 8BX
CountryUnited Kingdom
Phone number (incl. country code)01752764403
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)Yes
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects1312
Additional information
Sample size calculated for the primary endpoint of time to treatment failure, assuming that median time to treatment failure in the control arm is 90 days. An estimated 88 GP practices per arm, and a total sample size of 1312 patients.
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Effectiveness evaluation
Primary scope : Disease epidemiology
12. Main objective(s)
What is the main objective of the study?
The primary objective of this study is to assess the time to treatment failure in patients on Ultibro®+add-on device+app (“adherence support arm” [ASA]) compared with patients receiving usual routine clinical care. This assessment will focus on patients who are suitable for, and accept the add-on device/app technology (primary populations).
2
Are there primary outcomes?Yes
Time to treatment failure, where treatment failure is defined as the first occurrence of:
• Moderate/severe COPD exacerbation
• Prescription of triple therapy (ICS/LABA/LAMA)
• Prescription of additional chronic therapy
• Respiratory-related death
Are there secondary outcomes?Yes
1) Adherence (based on prescription (Rx) refill records over 12 months)
2) Moderate/severe exacerbations (in terms of the proportion of patients with at least one moderate/severe exacerbation at 12 months, and total number of exacerbations at 12 months)
13. Study design
What is the design of the study?
Randomised controlled trial
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
For primary analysis, time-to-event analysis will be performed to analyse the association between intervention and time to first outcome event (treatment failure) with censoring at the time of death or loss to follow-up.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
